HIGHLIGHTS
- who: Roberto Cairoli from the Gemtuzumab ozogamicin, leukemia, study, Cost-effectiveness, Italy have published the Article: Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy, in the Journal: (JOURNAL)
- what: In this analysis the authors assessed the cost-effectiveness of GO in combination with daunorubicin and cytarabine (DA) vs DA alone adopting the perspective of the Italian National Health Service. Methods For this analysis a cohort state transition model was developed. In the model, patients who maintain remission for at least 60 months are . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.